Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease
Status:
Completed
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
Subjects enrolled in this study will be evaluated for immune responses and histological
changes in the small bowel following 2 doses of TIMP-GLIA or placebo and a 14-day oral gluten
challenge.
Phase:
Phase 2
Details
Lead Sponsor:
COUR Pharmaceutical Development Company, Inc. Takeda